Agents targeting human epidermal growth factor receptor 2 (Her2), hormone receptors, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and immune checkpoints have completely changed the paradigm of breast cancer treatment [3–9]. Here, ERBB2 is linked to breast carcinoma.